clofazimine has been researched along with Babesia Infection in 4 studies
Clofazimine: A fat-soluble riminophenazine dye used for the treatment of leprosy. It has been used investigationally in combination with other antimycobacterial drugs to treat Mycobacterium avium infections in AIDS patients. Clofazimine also has a marked anti-inflammatory effect and is given to control the leprosy reaction, erythema nodosum leprosum. (From AMA Drug Evaluations Annual, 1993, p1619)
clofazimine : 3-Isopropylimino-3,5-dihydro-phenazine in which the hydrogen at position 5 is substituted substituted by a 4-chlorophenyl group, and that at position 2 is substituted by a (4-chlorophenyl)amino group. A dark red crystalline solid, clofazimine is an antimycobacterial and is one of the main drugs used for the treatment of multi-bacillary leprosy. However, it can cause red/brown discolouration of the skin, so other treatments are often preferred in light-skinned patients.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with clofazimine alone, clofazimine plus azithromycin, and atovaquone plus azithromycin was ineffective and failed to eliminate the parasites completely, while a 44-day treatment with clofazimine plus atovaquone was highly effective and resulted in a radical cure." | 1.72 | Combination of Clofazimine and Atovaquone as a Potent Therapeutic Regimen for the Radical Cure of Babesia microti Infection in Immunocompromised Hosts. ( Ahedor, B; Batmagnai, E; Igarashi, I; Liu, M; Nugraha, AB; Otgonsuren, D; Sivakumar, T; Tuvshintulga, B; Xuan, X; Yokoyama, N, 2022) |
| " Additional preclinical studies are required to identify the minimal dose and dosage of CFZ for babesiosis." | 1.56 | Clofazimine, a Promising Drug for the Treatment of Babesia microti Infection in Severely Immunocompromised Hosts. ( Gantuya, S; Guswanto, A; Igarashi, I; Krause, PJ; Sivakumar, T; Tayebwa, DS; Tuvshintulga, B; Vannier, E; Yokoyama, N, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 4 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Vannier, E | 2 |
| Gelfand, JA | 1 |
| Tuvshintulga, B | 2 |
| Sivakumar, T | 2 |
| Nugraha, AB | 1 |
| Ahedor, B | 1 |
| Batmagnai, E | 1 |
| Otgonsuren, D | 1 |
| Liu, M | 1 |
| Xuan, X | 1 |
| Igarashi, I | 3 |
| Yokoyama, N | 2 |
| Rizk, MA | 1 |
| Baghdadi, HB | 1 |
| El-Sayed, SAE | 1 |
| Eltaysh, R | 1 |
| Tayebwa, DS | 1 |
| Gantuya, S | 1 |
| Guswanto, A | 1 |
| Krause, PJ | 1 |
4 other studies available for clofazimine and Babesia Infection
| Article | Year |
|---|---|
Clofazimine for Babesiosis: Preclinical Data Support a Clinical Trial.
Topics: Antitubercular Agents; Babesiosis; Clofazimine; Humans | 2022 |
Combination of Clofazimine and Atovaquone as a Potent Therapeutic Regimen for the Radical Cure of Babesia microti Infection in Immunocompromised Hosts.
Topics: Animals; Anti-Bacterial Agents; Antiprotozoal Agents; Atovaquone; Azithromycin; Babesia microti; Bab | 2022 |
Repurposing of the Malaria Box for Babesia microti in mice identifies novel active scaffolds against piroplasmosis.
Topics: Animals; Atovaquone; Babesia microti; Babesiosis; Clofazimine; Cysteine Proteases; Drug Repositionin | 2022 |
Clofazimine, a Promising Drug for the Treatment of Babesia microti Infection in Severely Immunocompromised Hosts.
Topics: Amino Acid Sequence; Animals; Babesia microti; Babesiosis; Clofazimine; Cytochromes b; Disease Model | 2020 |